To assess the difference in best-corrected visual acuity (BCVA) at presentation between the first and second eye in patients with bilateral neovascular age-related macular degeneration (AMD).
Methods
We reviewed the charts of all patients who had a clinical examination for neovascular AMD at the University Eye Clinic of Creteil in January 2013. We retrospectively analyzed demographic and clinical data for 264 patients.
Results
In the fellow eye, choroidal neovascularization (CNV) developed in 75/264 patients (28.4%) with a time interval between the 2 events of 30.3 months (range 6-145). Data were available on 65 patients: 14/65 (21.5%) were asymptomatic, 24/65 (36.9%) had BCVA >20/40, whereas at the time of CNV diagnosis in the first eye, no patient was asymptomatic (p<0.0001), and 11/65 (16.9%) eyes had BCVA >20/40 (p<0.0001). The mean BCVA of the first affected eye was 0.68 (±0.41) logarithm of minimum angle of resolution (logMAR) and the mean BCVA for the second eye was 0.36 (±0.29) logMAR (p<0.0001).
Conclusions
The BCVA at the time of diagnosis of CNV was higher in the second eye than in the first affected eye. This was possibly due to several factors including systematic bilateral examination in follow-up of unilateral exudative AMD that allowed detection of 20% of cases.
KlaverCCWolfsRCVingerlingJRHofmanAde JongPTAge-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol1998116653–8.
2.
SmithWAssinkJKleinRRisk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology2001Apr1084697–704.
3.
OwenCGJarrarZWormaldRCookDGFletcherAERudnickaARThe estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol201296752–6.
4.
BrownDMKaiserPKMichelsM; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med20063551432–44.
5.
RosenfeldPJBrownDMHeierJS; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med20063551419–31.
6.
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol200914843–58.
7.
MataixJPalaciosECarmenDMGarcia-PousMNaveaACombined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. Retina2010301190–6.
8.
SpielbergLLeysATreatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol2010248943–56.
9.
QuerquesGAzryaSMartinelliDRanibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol201094292–6.
10.
Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol19931111189–99.
11.
GangnonRELeeKEKleinBEKSeverity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study. JAMA Ophthalmol2015133125–32.
12.
BaunOVindingTKroghENatural course in fellow eyes of patients with unilateral age-related exudative maculopathy. A fluorescein angiographic 4-year follow-up of 45 patients. Acta Ophthalmol199371398–401.
13.
SolomonSDJefferysJLHawkinsBSBresslerNMSubmacular Surgery Trials Research Group. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report no. 20 from the Submacular Surgery Trials Research Group. Arch Ophthalmol20071251323–30.
14.
LechanteurYTvan de VenJPSmailhodzicDGenetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration. Invest Ophthalmol Vis Sci2012535846–52.
15.
MaguireMGDanielEShahAR; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology20131202035–41.
16.
LichtingerACarazaMGalbinurTChowersIFactors associated with early detection of choroidal neovascularization in age-related macular degeneration in the clinic setting. Isr Med Assoc J201214363–6.
17.
BoyerDSAntoszykANAwhCCBhisitkulRBShapiroHAcharyaNRMARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology2007114246–52.
18.
KaiserPKBrownDMZhangKRanibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol2007144850–7.
19.
LimJHWickremasingheSSXieJDelay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol2012153678–86.
20.
HeierJSBrownDMChongV; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology20121192537–48.
21.
MaguireMGDanielEShahAR; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology20131202035–41.
22.
GudnadottirGSMagnussonKPStefanssonEJonassonFHelgadottirGSigurdssonHThe time pattern of bilateral exudative age-related macular degeneration. Acta Ophthalmol Scand200583333–6.
23.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol20011191417–36.
24.
LevezielNPucheNRichardFGenotypic influences on severity of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci2010512620–5.
